Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
Provided By GlobeNewswire
Last update: Mar 31, 2025
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments.
Read more at globenewswire.com
